{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GEn+1200mg",
    "query": {
      "intervention": "GEn 1200mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T20:05:15.471Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01516372",
      "title": "A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Restless Legs Syndrome"
      ],
      "interventions": [
        {
          "name": "GEn 1200mg",
          "type": "DRUG"
        },
        {
          "name": "Gen 6000 mg",
          "type": "DRUG"
        },
        {
          "name": "GEn Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XenoPort, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 52,
      "start_date": "2012-01",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2021-04-12",
      "last_synced_at": "2026-09-02T20:05:15.471Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01516372"
    },
    {
      "nct_id": "NCT00619476",
      "title": "A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuralgia, Postherpetic"
      ],
      "interventions": [
        {
          "name": "GEn 1200mg/day",
          "type": "DRUG"
        },
        {
          "name": "GEn 2400mg/day",
          "type": "DRUG"
        },
        {
          "name": "GEn 3600mg/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XenoPort, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 376,
      "start_date": "2008-02",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-09-02T20:05:15.471Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Northport, Alabama • Chandler, Arizona + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00619476"
    },
    {
      "nct_id": "NCT01191697",
      "title": "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2011-02",
      "completion_date": "2024-08",
      "has_results": true,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-09-02T20:05:15.471Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01191697"
    },
    {
      "nct_id": "NCT00617461",
      "title": "A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuralgia, Postherpetic"
      ],
      "interventions": [
        {
          "name": "GEn 1200mg/day",
          "type": "DRUG"
        },
        {
          "name": "GEn 3600mg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XenoPort, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2008-03",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-09-02T20:05:15.471Z",
      "location_count": 42,
      "location_summary": "Phoenix, Arizona • Oxnard, California • Roseville, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00617461"
    },
    {
      "nct_id": "NCT00643760",
      "title": "A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuropathy, Diabetic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "GEn 1200mg/day",
          "type": "DRUG"
        },
        {
          "name": "GEn 2400mg/day",
          "type": "DRUG"
        },
        {
          "name": "GEn 3600mg/day",
          "type": "DRUG"
        },
        {
          "name": "Pregabalin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XenoPort, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 421,
      "start_date": "2008-03",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-09-02T20:05:15.471Z",
      "location_count": 90,
      "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00643760"
    }
  ]
}